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Abstract
Introduction: Endothelial dysfunction is an early step in the atherosclerotic process and can be quantified by
flow-mediated vasodilation (FMD). Our aim was to investigate the effect of long-term rosuvastatin therapy on
endothelial function in patients with inflammatory joint diseases (IJD) with established atherosclerosis. Furthermore,
to evaluate correlations between change in FMD (ΔFMD) and change in carotid plaque (CP) height, arterial stiffness
[aortic pulse wave velocity (aPWV) and augmentation index (AIx)], lipids, disease activity and inflammation.
Methods: Eighty-five statin-naïve patients with IJD and ultrasound-verified CP (rheumatoid arthritis: n = 53, ankylosing
spondylitis: n = 24, psoriatic arthritis: n = 8) received rosuvastatin treatment for 18 months. Paired-samples t tests were
used to assess ΔFMD from baseline to study end. Linear regression models were applied to evaluate correlations
between ΔFMD and cardiovascular risk factors, rheumatic disease variables and medication.
Results: The mean ± SD FMD was significantly improved from 7.10 ± 3.14 % at baseline to 8.70 ± 2.98 % at study end
(p < 0.001). Improvement in AIx (p < 0.05) and CP height reduction (p = 0.001) were significantly associated with ΔFMD
(dependent variable).
Conclusions: Long-term lipid lowering with rosuvastatin improved endothelial function in IJD patients with
established atherosclerotic disease. Reduced arterial stiffness and CP regression were longitudinally correlated
with the improvement in endothelial function measured by FMD.
Trial registration: ClinicalTrials.gov NCT01389388. Registered 16 April 2010.
Introduction
Patients with inflammatory joint diseases (IJD), including
rheumatoid arthritis (RA), ankylosing spondylitis (AS) and
psoriatic arthritis (PsA) have reduced endothelial function
compared to the general population [1]. According to hy-
potheses regarding development of atherosclerosis, the
progressive impairment of endothelial function is an early
step in the developing process of atherosclerotic plaques
[2]. Furthermore, restoration of endothelial function has
been proposed as an important mediator of atheroscler-
otic regression [3].
Flow-mediated vasodilation (FMD) of the brachial artery
is a widely used noninvasive technique that quantifies
endothelial function [4]. Reduced FMD has been shown to
predict cardiovascular disease (CVD) events in other
high-risk populations and in the general population [5].
Moreover, decreasing FMD correlates with the presence
of carotid plaques (CP) [6], which are highly prevalent in
RA patients [7]. The European recommendations on CVD
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prevention classify CP as a very high CVD risk factor [8].
Due to the ethical implications of not giving statin therapy
to patients with CP, the ROsuvastatin in Rheumatoid
Arthritis, Ankylosing Spondylitis and other inflammatory
joint diseases (RORA-AS) study was a single-arm statin
study from which we have previously reported that rosu-
vastatin therapy induced CP height regression in IJD
patients [9].
The main objective of the present secondary endpoint
analyses from the RORA-AS study was to evaluate the ef-
fect of long-term lipid lowering with rosuvastatin on FMD
in IJD patients with established atherosclerotic disease.
Furthermore, we aimed to examine if the change in FMD
(ΔFMD) induced by rosuvastatin would be correlated with
CP height reduction. In addition, we evaluated if ΔFMD
from baseline to study end could be predicted by, or was
correlated with, the baseline levels of or the longitudinal
changes in arterial stiffness, lipids, inflammatory parame-
ters, rheumatic disease activity, carotid intima-media
thickness (c-IMT) or rosuvastatin dose.
Methods
The study design of the open, prospective RORA-AS
study has previously been described in detail [9]. In
short, IJD patients with ultrasound-verified CP were
treated with rosuvastatin for 18 months. The initial
rosuvastatin dose (20 mg once daily (o.d.), except for pa-
tients > 70 years who received 5 mg) was doubled every
fortnight, until low-density lipoprotein (LDL-c) target
(<1.8 mmol/L) or maximal rosuvastatin dose (40 mg
o.d.) was reached. The LDL-c target was defined in ac-
cordance with the most recent European guidelines [8].
The feasibility of reaching this target in IJD patients with
low rates of adverse events has previously been reported
[9, 10]. All patients signed an informed consent and the
study was approved by the Norwegian South East
Regional Health committee and registered with Clinical-
Trials.gov Id: NCT01389388. The European Union Drug
Regulating Authorities Clinical Trials (EudraCT) num-
ber is 2008-005551-20.
Endothelial function was assessed by the FMD method
[4]. As the FMD measurement is dynamic in nature and
can be impacted by several factors, all recordings were
performed in fasting patients, including no smoking or
medication. In addition, all RORA-AS study visits were
independent from other visits to the rheumatology out-
patient clinic throughout the study. Accordingly, there
existed no systematic tendency toward the administration
of disease-modifying antirheumatic drugs (DMARDs) in
the days prior to the FMD measurements that would
influence the results. All recordings were done with the
patient in a supine position using a Vivid 7 scanner (GE
Vingmed Ultrasound, Horten, Norway) with a 10 MHz
transducer that was placed in a fixed position and
stabilized with a custom-made tripod to optimize the sta-
bility. The results were analyzed offline from jpg images
extracted from video files using Brachial Analyzer software
(Medical Imaging Applications LLC, Coralville, IA, USA).
FMD percentage was calculated as the percentage change
between the baseline diameter and the largest diameter of
the brachial artery within the first 2 minutes after 5
minutes occlusion of the right forearm. The examiner had
no information pertaining to further patient characteris-
tics. Recordings were performed and analyses were super-
vised by the same experienced ultrasonographer (JH) in
accordance with international guidelines [4], and the
intra- and inter-reader reliability for FMD showed a good
correlation (intraclass correlations = 0.96 for both). Flow
of the brachial artery was not obtained during the FMD
examinations. The mean diameter of the brachial artery
for all patients at both baseline and 18 months was plotted
against time from 0 to 120 seconds and the area under the
curve (AUC0–120) for both graphs were calculated as a
millimeters multiplied with seconds (mm× sec) value.
To assess arterial stiffness, augmentation index (AIx)
and aortic pulse wave velocity (aPWV) were measured by
the Sphygmocor apparatus (Atcor Medical Pty Ltd., West
Ryde, Australia) according to guidelines and as previously
described [11].
Statistics
Descriptive statistics are expressed as number (%) for
dichotomized variables, and mean ± standard deviation
(SD) and median and interquartile range (IQR) for nor-
mally and non-normally distributed variables, respect-
ively. Diagnosis groups were compared using analysis of
variance (ANOVA), and chi-square tests as appropriate,
in addition to the nonparametric Kruskal-Wallis test for
number of CP. Non-normally distributed variables were
logarithmically transformed.
The change in FMD from baseline to study end was
analyzed using a paired-samples t test.
Both adjusted and unadjusted linear regression ana-
lyses with ΔFMD as the dependent variable were
applied to:
1) Evaluate if ΔFMD could be predicted by baseline
demographic data (age, gender), use of biologic
DMARDs (bDMARDs), inflammation [C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR)],
rheumatic disease activity [disease activity score in 28
joints (DAS28), ankylosing spondylitis disease activity
score (ASDAS) or lipids [(low-density lipoprotein
(LDL-c), high-density lipoprotein (HDL-c)]
2) Explore if ΔFMD was correlated with the changes in
CP height, inflammation, rheumatic disease activity,
lipids, arterial stiffness, c-IMT and rosuvastatin dose
from baseline to study end
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Model assumptions and validity were assessed
using residuals. Two-sided p values <0.05 were con-
sidered significant. Statistical analyses were
performed using the Statistical Package for the Social
Sciences version 21 (IBM SPSS Statistics for
Windows, Armonk, NY, USA).
Table 1 Patient characteristics
RA AS PsA All p value
RA/AS/PsA
Number, n (%) 53 24 8 85
Age, median (IQR) 61.0 (56.0–68.0) 59.5 (53.5–64.0) 62.0 (56.3–66.5) 61.0 (56.0–67.0) 0.26
Sex female/male, n (%) 40/13 (75.5/24.5) 8/16 (33.3/66.7) 3/5 (37.5/62.5) 51/34 (60.0/40.0) 0.001
Disease duration, median (IQR) 16.0 (8.0–22.8) 23.5 (11.5–30.0) 14.0 (4.0–30.5) 18.0 (8.3–26.0) 0.29
DAS28, mean ± SD 2.51 ± 0.88 – – – –
ASDAS, mean ± SD – 5.96 ± 2.95 – – –
CVD risk factors
Smoke, n (%) 10 (18.9) 3 (12.5) 1 (12.5) 14 (16.5) 0.75
BMI, mean ± SD 25.1 ± 3.3 25.2 ± 2.6 25.9 ± 2.9 25.2 ± 3.1 0.81
TC (mmol/L), mean ± SD 6.41 ± 1.20 6.25 ± 0.87 6.24 ± 1.17 6.35 ± 1.11 0.81
HDL-c (mmol/L), mean ± SD 1.83 ± 0.53 1.53 ± 0.43 1.45 ± 0.31 1.71 ± 0.50 0.02
TG (mmol/L), median (IQR) 1.21 (0.89–1.57) 1.44 (1.02–1.99) 1.13 (0.78–2.70) 1.22 (0.89–1.75) 0.40
LDL-c (mmol/L), mean ± SD 3.98 ± 1.09 4.03 ± 0.85 4.10 ± 0.97 4.01 ± 1.01 0.95
sBP (mmHg), mean ± SD 142.8 ± 21.7 144.8 ± 14.3 151.1 ± 25.3 144.1 ± 20.2 0.55
dBP (mmHg), mean ± SD 83.2 ± 9.2 84.6 ± 8.5 88.5 ± 11.5 84.1 ± 9.3 0.30
Comorbidities, n (%)
HT 32 (60.4) 17 (70.8) 6 (75.0) 55 (64.7) 0.55
Diabetes 4 (7.5) 2 (8.3) 1 (12.5) 7 (8.2) 0.84
CVD 5 (9.4) 4 (16.7) 0 (0) 9 (10.6) 0.38
CP, median (range) 1.0 (1.0–2.0) 1.0 (1.0–3.0) 2.5 (2.0–3.0) 1.0 (1.0–2.0) 0.09
Biomarkers, mean ± SD
ESR (mm/h) 15.1 ± 10.3 16.2 ± 10.5 12.4 ± 9.8 15.9 ± 10.1 0.32
White blood cells (109/L) 7.38 ± 2.97 7.74 ± 3.44 6.68 ± 1.72 6.67 ± 1.37 0.54
CRP (mg/L), median (IQR) 3.00 (1.00–4.00) 1.00 (1.00–3.00) 4.00 (2.00–7.25) 2.00 (1.00–4.00) 0.16
Hb (g/100 mL) 14.1 ± 1.1 14.0 ± 1.0 14.4 ± 1.0 14.0 ± 1.2 0.25
Creatinine (μmol/L) 72.0 ± 13.4 70.9 ± 13.7 74.6 ± 13.9 70.8 ± 8.3 0.52
AST (U/L) 28.1 ± 10.1 28.2 ± 11.2 28.8 ± 9.5 24.9 ± 3.6 0.64
ALT (U/L) 29.8 ± 19.5 28.6 ± 19.6 32.4 ± 22.0 29.6 ± 8.6 0.74
CK (U/L) 78.2 ± 40.0 99.0 ± 48.1 66.4 ± 28.7 82.9 ± 42.5 0.08
Medication, n (%)
Prednisolone 17 (32.1) 2 (8.3) 2 (25.0) 21 (24.7) 0.08
NSAIDs 20 (37.7) 12 (50.0) 3 (37.5) 35 (41.2) 0.58
sDMARDs 32 (60.4) 6 (25.0) 7 (87.5) 45 (52.9) 0.002
bDMARDs 17 (32.1) 8 (33.3) 4 (50.0) 29 (34.1) 0.73
a-HT medication 16 (30.2) 4 (16.7) 2 (25.0) 22 (25.9) 0.45
RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, IQR interquartile range, DAS28 disease activity score in 28 joints, SD standard deviation,
ASDAS ankylosing spondylitis disease activity score, CVD cardiovascular disease, BMI body mass index, TC total cholesterol, HDL-c high-density lipoprotein
cholesterol, TG triglycerides, LDL-c low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, HT hypertension (self-reported
hypertension, blood pressure >140/90 mmHg or current use of antihypertensive medication), CP carotid plaque, ESR erythrocyte sedimentation rate, CRP
C-reactive protein, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, CK creatine kinase, NSAIDs nonsteroidal anti-inflammatory
drugs, DMARDs disease-modifying antirheumatic drug, sDMARDs synthetic DMARDs, bDMARDs biologic DMARDs, a-HT antihypertensive
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Fig. 1 Change in flow-mediated vasodilation (FMD) from baseline to study end. Change in flow-mediated vasodilation (FMD) (%) from baseline
to study end in patients with inflammatory joint diseases and established atherosclerosis (n = 85) after 18 months of rosuvastatin treatment.
FMD flow-mediated vasodilation, SE standard error, SD standard deviation
Fig. 2 Mean brachial artery diameter plotted against time at baseline and study end. Flow-mediated vasodilation (FMD) mean brachial artery
diameter (millimeters) plotted against time (seconds) in patients with inflammatory joint diseases and established atherosclerosis (n = 85), before
and after 18 months of rosuvastatin treatment
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Results
The RA (n = 53), AS (n = 24) and PsA (n = 8) patients
were comparable concerning baseline characteristics
(Table 1). However, we observed expected differences
concerning gender (p = 0.01), baseline HDL-c levels
(p = 0.02) and use of synthetic disease-modifying anti-
rheumatic drugs (sDMARDS) (p = 0.002), attributable
to the distinct characteristics of the three disease
entities. Changes in lipid levels and CP height in the
RORA-AS study has previously been reported [9]. An
additional table has been provided that shows these
changes in detail (see Additional file 1).
FMD was improved by 1.6 % from baseline to study end
(Fig. 1), reflecting a mean ± SD FMD of 7.10 ± 3.14 % and
8.70 ± 2.98 %, respectively (p < 0.001). Figure 2 shows the
relative change in vascular diameter as measured by FMD
from 0 to 120 seconds. The AUC0–120 of the baseline
measurements was increased by 27.7 % from baseline
(19.3 mm× sec) to study end (24.6 mm× sec).
The adjusted and unadjusted analyses did not reveal any
statistically significant predictors of ΔFMD in our study
(Table 2). However, in the adjusted linear regression ana-
lyses, the changes in AIx and CP height were associated
with ΔFMD, in the sense that patients who experienced re-
duced arterial stiffness measured by AIx and CP height re-
duction also had increased FMD (p < 0.05 and p = 0.001,
respectively). The estimates from the corresponding un-
adjusted linear regression analyses were comparable.
ΔFMD did not significantly correlate with baseline levels or
change in inflammatory biomarkers, rheumatic disease
activity, lipids, c-IMT or rosuvastatin dose in the linear
regression analyses.
Discussion
In the present study, we have shown that endothelial
function was significantly improved in IJD patients with
established atherosclerosis who received rosuvastatin
therapy for 18 months. Furthermore, we have demon-
strated that the amelioration of FMD was correlated
with CP regression and reduced arterial stiffness.
The improvement in FMD after statin treatment
observed in our study is supported by the positive effect
by statins on FMD reported from previous studies with
smaller IJD patient cohorts and shorter follow-up time
[12–14]. Interestingly, a meta-analysis by Inaba et al.
reported that 1 % lower FMD was associated with a 13 %
Table 2 Unadjusted and adjusted linear regression analyses with flow-mediated vasodilation (ΔFMD) as the dependent variable
Unadjusted analyses Adjusted analysesa
β (95 % CI) p value β (95 % CI) p value
Age −0.07 (−0.14, 0.01) 0.09 –
Gender 0.38 (−0.89, 1.66) 0.55 –
bDMARDs −1.07 (−2.31, 0.18) 0.09 –
CRP Baseline −0.01 (−0.18, 0.16) 0.92 −0.02 (−0.18, 0.15) 0.86
Change 0.04 (−0.01, 0.09) 0.13 0.05 (−0.01, 0.10) 0.08
ESR Baseline −0.01 (−0.07, 0.05) 0.83 0.01 (−0.06, 0.08) 0.76
Change 0.04 (−0.02, 0.09) 0.18 0.04 (−0.01, 0.09) 0.15
DAS28 Baseline 0.24 (−0.82, 1.29) 0.66 0.29 (−0.73, 1.31) 0.57
Change 0.02 (−1.23, 1.27) 0.98 −0.25 (−1.43, 0.93) 0.67
ASDAS Baseline −0.01 (−0.40, 0.38) 0.96 0.08 (−0.53, 0.68) 0.78
Change 0.14 (−0.31, 0.58) 0.52 0.14 (−0.52, 0.81) 0.63
LDL-c Baseline 0.01 (0.62, 0.63) 0.98 −0.13 (−0.75, 0.50) 0.69
Change −0.17 (−0.91, 0.57) 0.65 −0.06 (−0.80, 0.68) 0.87
HDL-c Baseline −0.54 (−1.78, 0.70) 0.39 −0.26 (−1.70, 1.17) 0.72
Change −1.33 (−3.18, 0.52) 0.16 −1.43 (−3.28, 0.42) 0.13
AIx, change −0.09 (−0.18, 0.01) 0.06 −0.09 (−0.18, 0.00) < 0.05
aPWV, change −0.07 (−0.58, 0.43) 0.78 −0.14 (−0.66, 0.38) 0.59
CP height, change −3.51 (−5.28, −1.73) < 0.001 −3.10 (−4.95, −1.25) 0.001
c-IMT, change 3.55 (−4.51, 11.62) 0.38 3.96 (−4.77, 12.70) 0.37
Rosuvastatin dose 0.02 (−0.03, 0.07) 0.48 0.01 (−0.04, 0.06) 0.76
bDMARDs biologic disease-modifying antirheumatic drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score in 28 joints,
ASDAS ankylosing spondylitis disease activity score, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, AIx augmentation index,
aPWV aortic pulse wave velocity, CP carotid plaque, c-IMT carotid intima-media thickness
aAdjusted for age, gender and use of bDMARDs
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increase in risk of future CVD events. Accordingly, the
1.6 % improvement in FMD observed in our study may re-
flect a highly beneficial clinical effect by rosuvastatin [15].
The negative influence of endothelial dysfunction on the
progression of atherosclerosis has previously been re-
ported [16]. We show for the first time that carotid ath-
erosclerosis regression was associated with improvement
of FMD in statin-treated patients. Thus, our results sup-
port the existing evidence that restoration of endothelial
function may be essential in the reversal of atherosclerosis
[3]; however, studies to elucidate further details in this
pathological process are warranted.
AIx and aPWV are predictors of CVD in the general
population [17, 18] and are reported to be higher in
patients with IJD [1]. The inverse relation between FMD
and arterial stiffness in IJD patients has previously been
described [19]. To our knowledge, this is the first report
on longitudinal correlation between improved endothelial
function and decreasing arterial stiffness. Although endo-
thelial dysfunction and arterial stiffness represent different
aspects of vascular disease, the pathogeneses of these vas-
cular biomarkers are closely related [20]. Our results indi-
cate that these biomarkers are also related in the process
of atherosclerotic regression.
We found no significant correlation between ΔFMD
and the levels of inflammatory biomarkers or rheumatic
disease activity in our patients. This may be due to that
the patients were largely well treated at baseline and
throughout the study.
The lack of a placebo group in the RORA-AS study rep-
resents a possible limitation. However, as aging is related to
progressive impairment of endothelial function [21], it is
unlikely that the improved FMD in our study was a result
of natural progression. Data concerning flow of the brachial
artery in relation to the FMD measurements would have
been preferable; however, such data were not obtained.
Conclusions
In conclusion, endothelial function was significantly im-
proved in IJD patients with established atherosclerosis
receiving long-term lipid-lowering therapy with rosuvas-
tatin. The amelioration of FMD was correlated with
reduced arterial stiffness and decreasing CP height and
support the hypothesis that restoration of endothelial
function is closely related to atherosclerotic regression.
Additional file
Additional file 1: Changes in lipid levels and carotid plaque height
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study end. It also shows the mean change and corresponding p values
for these parameters during the course of the study. (PDF 185 kb)
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